Two 10-year-olds accused of exchanging gun for money on school groundsSWFL could feel economic impacts of Baltimore bridge collapse
Over 30 million Americans have diabetes. Photo via CBS News. The injection of a lifetime is in the works. A revolutionary drug could soon be approved to delay Type 1 diabetes. We looked at how the shot would work, what it will take for it to become a reality and spoke to those for whom this would be a game changer. About three years ago, doctors diagnosed Stephanie Rochelle’s son, Finn, with Type 1 diabetes. “They finger pricked him, and his sugar then was 380,” Rochelle said. Rochelle says — because Finn was so little — doctors had difficulty drawing his blood and had to pin him down. But the strain followed the family outside of the hospital too. “Eight, 10, 12 finger pricks a day. Eight, 10, 12 injections a day,” Rochelle explained. “I had to quit my job. I walked away from a very good career.” Rochelle says Finn needed constant care to manage his diabetes. But as he’s getting older, it’s getting easier. “He is understanding if I say, ‘Give yourself 50 carbs; treat yourself for 50 carbs,’” Rochelle said. “He knows what it is. At two, he obviously can’t do it himself.” A new drug is offering hope to families like Rochelle’s. Teplizumab is an injection that stops the immune cells that trigger Type 1 diabetes. Trial patients received two weeks of treatment. More than 900 day later, 50% of patients remained diabetes free. Back in May, and FDA advisory panel voted in favor of approving the drug. The FDA is expected to make a final decision Friday, July 2. Rochelle says, while it isn’t a cure, the extra time would be a great step forward. “I probably would have kept my job at least a little while longer until we could have figured out a solution to our problem,” Rochelle said. “The learning curve wouldn’t have been so big.” MORE: Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D) Teplizumab Participant Resources